Active — Not RecruitingPhase 1

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Egypt120 participantsStarted 2023-09-01

Plain-language summary

Assess serum and tissue retinol binding protein 4 in patients with severe alopecia areata in correlation with healthy individuals . Estimate genetic profile of retinol binding protein4 in severe alopecia areata patients Assess possible role of retinol binding protein 4 genetic mutation in response to barcitinib treatment in patients with severe alopecia areata .

Who can participate

Age range12 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients at least 12 years old not more than 60 with severe alopecia areata, multiple or /with not responding to usual treatment Exclusion Criteria: * Patients with scarring alopecia. * Patients less than 12 years old or more than 60. * Patients with active inflammatory disease or immuncompromised. * Patients with infection or malignancy . * Patients with antiepileptic drugs or psychotics . * Pregnancy and lactation . * Patients with abnormal lipid profile. * Patients with bleeding or thrombotic tendency. * Patients taking other JAK inhibitors or cyclosporine or immunosuppressive drugs. * Patients with active herpes zoster or have tendency for recurrence.

What they're measuring

Assess serum and tissue retinol binding protein 4 in patients with severe alopecia

Timeframe: baseline

Trial details

NCT IDNCT06545110

SponsorSouth Valley University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-30

View on ClinicalTrials.gov More Alopecia Areata trials